Search

Your search keyword '"Gule-Monroe, Maria"' showing total 151 results
Start Over Author "Gule-Monroe, Maria"
151 results on '"Gule-Monroe, Maria"'

2. The Use of Quantitative Metrics and Machine Learning to Predict Radiologist Interpretations of MRI Image Quality and Artifacts

Author

McCullum, Lucas, Wood, John, Gule-Monroe, Maria, Liu, Ho-Ling Anthony, Chen, Melissa, Shah, Komal, Chasen, Noah Nathan, Kumar, Vinodh, Hou, Ping, Stafford, Jason, Chung, Caroline, Ahmad, Moiz, Walker, Christopher, and Yung, Joshua

Subjects
Physics - Medical Physics
Abstract

A dataset of 3D-GRE and 3D-TSE brain 3T post contrast T1-weighted images as part of a quality improvement project were collected and shown to five neuro-radiologists who evaluated each sequence for both image quality and imaging artifacts. The same scans were processed using the MRQy tool for objective, quantitative image quality metrics. Using the combined radiologist and quantitative metrics dataset, a decision tree classifier with a bagging ensemble approach was trained to predict radiologist assessment using the quantitative metrics. A machine learning model was developed for the following three tasks: (1) determine the best model / performance for each MRI sequence and evaluation metric, (2) determine the best model / performance across all MRI sequences for each evaluation metric, and (3) determine the best general model / performance across all MRI sequences and evaluations. Model performance for imaging artifact was slightly higher than image quality, for example, the final generalized model AUROC for image quality was 0.77 (0.41 - 0.84, 95% CI) while imaging artifact was 0.78 (0.60 - 0.93, 95% CI). Further, it was noted that the generalized model performed slightly better than the individual models (AUROC 0.69 for 3D-GRE image quality, for example), indicating the value in comprehensive training data for these applications. These models could be deployed in the clinic as automatic checks for real-time image acquisition to prevent patient re-scanning requiring another appointment after retrospective radiologist analysis or improve reader confidence in the study. Further work needs to be done to validate the model described here on an external dataset. The results presented here suggest that MRQy could be used as a foundation for quantitative metrics as a surrogate for radiologist assessment.

Published
2023

5. ACR Appropriateness Criteria® Tinnitus: 2023 Update

Author

Jain, Vikas, Policeni, Bruno, Juliano, Amy F., Adunka, Oliver, Agarwal, Mohit, Dubey, Prachi, Friedman, Elliott R., Gule-Monroe, Maria K., Hagiwara, Mari, Hunt, Christopher H., Lo, Bruce M., Oh, Esther S., Rath, Tanya J., Roberts, J. Kirk, Schultz, David, Taheri, M. Reza, Zander, David, and Burns, Judah

Published
2023
Full Text
View/download PDF

6. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update

Author

Rath, Tanya J., Policeni, Bruno, Juliano, Amy F., Agarwal, Mohit, Block, Alec M., Burns, Judah, Conley, David B., Crowley, R. Webster, Dubey, Prachi, Friedman, Elliott R., Gule-Monroe, Maria K., Hagiwara, Mari, Hunt, Christopher H., Jain, Vikas, Powers, William J., Rosenow, Joshua M., Taheri, M. Reza, DuChene Thoma, Kate, Zander, David, and Corey, Amanda S.

Published
2022
Full Text
View/download PDF

8. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy.

Author

Hamidi, Sarah, Ning, Matthew S, Phan, Jack, Zafereo, Mark E, Gule-Monroe, Maria K, and Dadu, Ramona

Subjects
IMMUNE checkpoint inhibitors, EXTERNAL beam radiotherapy, SKULL base, THYROID cancer, CANCER treatment, STEREOTACTIC radiosurgery, IODINE isotopes, CETUXIMAB
Abstract

A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurgery to the brain and skull base lesions. Thereafter, as no targetable genetic alteration was identified and antiangiogenic multikinase inhibitors were deemed at high risk of hemorrhagic complications, off-label systemic therapies were considered. The mechanistic target of rapamycin (mTOR) inhibitor everolimus could not be obtained due to lack of insurance coverage, so the patient was treated with single-agent pembrolizumab. He showed an initial remarkable response, but unfortunately had disease progression in the neck and upper mediastinum after 1 year of therapy. At that time, he was treated with external beam radiotherapy, with concomitant pembrolizumab. He was then found to have an CTSB::ALK fusion, which has previously been described in 2 cases of thyroid cancer. However, as he showed a positive response to radiation with pembrolizumab, he continued single-agent immune checkpoint inhibition and had a persistent marked response almost a year after completing radiation. The patient was then followed at an outside institution and was transitioned to hospice at time of progression per his preference. He died 4 years after his initial diagnosis. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

9. ACR Appropriateness Criteria® Sinonasal Disease: 2021 Update

Author

Hagiwara, Mari, Policeni, Bruno, Juliano, Amy F., Agarwal, Mohit, Burns, Judah, Dubey, Prachi, Friedman, Elliott R., Gule-Monroe, Maria K., Jain, Vikas, Lam, Kent, Patino, Maria, Rath, Tanya J., Shian, Brian, Subramaniam, Rathan M., Taheri, M. Reza, Zander, David, and Corey, Amanda S.

Published
2022
Full Text
View/download PDF

11. ACR Appropriateness Criteria® Parathyroid Adenoma

Author

Zander, David, Bunch, Paul M., Policeni, Bruno, Juliano, Amy F., Carneiro-Pla, Denise, Dubey, Prachi, Gule-Monroe, Maria K., Hagiwara, Mari, Hoang, Jenny K., Jain, Vikas, Kim, Lawrence T., Moonis, Gul, Parsons, Matthew S., Rath, Tanya J., Solórzano, Carmen C., Subramaniam, Rathan M., Taheri, M. Reza, DuChene Thoma, Kate, Trout, Andrew T., Zafereo, Mark E., Jr., and Corey, Amanda S.

Published
2021
Full Text
View/download PDF

16. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.

Author

O'Brien, Barbara Jane, primary, Murthy, Rashmi Krishna, additional, Berry, Donald A., additional, Singareeka Raghavendra, Akshara, additional, Gule-Monroe, Maria, additional, Johnson, Jason M., additional, Schwartz-Gomez, Jill, additional, Topletz-Erickson, Ariel, additional, Lobbous, Mina, additional, Melisko, Michelle E., additional, Morikawa, Aki, additional, Ferguson, Sherise D., additional, de Groot, John Frederick, additional, Krop, Ian E., additional, Valero, Vicente, additional, Rimawi, Mothaffar F., additional, Wolff, Antonio C., additional, Tripathy, Debashish, additional, Lin, Nancy U., additional, and Stringer-Reasor, Erica Michelle, additional

Published
2024
Full Text
View/download PDF

17. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.

Author

Hamidi, Sarah, primary, Dadu, Ramona, additional, Ferrarotto, Renata, additional, Gule-Monroe, Maria, additional, Liu, Suyu, additional, Fellman, Bryan M., additional, Williams, Michelle D., additional, Zafereo, Mark E., additional, Wang, Rui Jennifer, additional, Lu, Charles, additional, Ning, Matthew S., additional, McKinley, Brian, additional, Woodman, Scott Eric, additional, Duose, Dzifa Yawa, additional, Gunn, Gary Brandon, additional, Busaidy, Naifa Lamki, additional, and Cabanillas, Maria E., additional

Published
2024
Full Text
View/download PDF

24. Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma

Author

Machol, Keren, Jankovic, Joseph, Vijayakumar, Dhanya, Burrage, Lindsay C., Jain, Mahim, Lewis, Richard A., Fuller, Gregory N., Xu, Mingchu, Penas-Prado, Marta, Gule-Monroe, Maria K., Rosenfeld, Jill A., Chen, Rui, Eng, Christine M., Yang, Yaping, Lee, Brendan H., Moretti, Paolo M., Dhar, Shweta U., Alejandro, Mercedes E., Azamian, Mahshid S., Bacino, Carlos A., Balasubramanyam, Ashok, Bostwick, Bret L., Burrage, Lindsay C., Chen, Shan, Clark, Gary D., Craigen, William J., Dhar, Shweta U., Emrick, Lisa T., Goldman, Alica M., Hanchard, Neil A., Jamal, Fariha, Karaviti, Lefkothea, Lalani, Seema R., Lee, Brendan H., Lewis, Richard A., Marom, Ronit, Moretti, Paolo M., Murdock, David R., Nicholas, Sarah K., Orange, Jordan S., Orengo, James P., Posey, Jennifer E., Potocki, Lorraine, Rosenfeld, Jill A., Samson, Susan L., Scott, Daryl A., Tran, Alyssa A., Vogel, Tiphanie P., Bellen, Hugo J., Wangler, Michael F., Yamamoto, Shinya, Eng, Christine M., Muzny, Donna M., Ward, Patricia A., Yang, Yaping, Goldstein, David B., Stong, Nicholas, Cope, Heidi, Jiang, Yong-hui, McConkie-Rosell, Allyn, Pena, Loren DM., Schoch, Kelly, Shashi, Vandana, Spillmann, Rebecca C., Sullivan, Jennifer A., Tan, Queenie K.G., Walley, Nicole M., Aaron, Aday, Beggs, Alan H., Briere, Lauren C., Cooper, Cynthia M., Donnell-Fink, Laurel A., High, Francis, Korrick, Susan, Krieg, Elizabeth L., Krier, Joel B., Lincoln, Sharyn A., Loscalzo, Joseph, Maas, Richard L., MacRae, Calum A., Pallais, J. Carl, Rodan, Lance H., Silverman, Edwin K., Stoler, Joan M., Sweetser, David A., Walker, Melissa, Walsh, Chris A., Esteves, Cecilia, Glanton, Emily, Holm, Ingrid A., Kohane, Isaac S., McCray, Alexa T., Might, Matthew, LeBlanc, Kimberly, Bick, David P., Birch, Camille L., Boone, Braden E., Brown, Donna M., Dorset, Daniel C., Handley, Lori H., Jones, Angela L., Lazar, Jozef, Levy, Shawn E., May, Thomas, Newberry, J. Scott, Schroeder, Molly C., Worthey, Elizabeth A., Batzli, Gabriel F., Dayal, Jyoti G., Eckstein, David J., Gould, Sarah E., Howerton, Ellen M., Krasnewich, Donna M., Mamounas, Laura A., Manolio, Teri A., Mulvihill, John J., Urv, Tiina K., Wise, Anastasia L., Brush, Matthew, Gourdine, Jean-Philippe F., Haendel, Melissa, Koeller, David M., Kyle, Jennifer E., Metz, Thomas O., Waters, Katrina M., Webb-Robertson, Bobbie-Jo M., Ashley, Euan A., Bernstein, Jonathan A., Bonner, Devon, Coakley, Terra R., Davidson, Jean M., Dries, Annika M., Enns, Gregory M., Fernandez, Liliana, Fisher, Paul G., Friedman, Noah D., Hom, Jason, Huang, Yong, Kohler, Jennefer N., Majcherska, Marta M., Marwaha, Shruti, McCormack, Colleen E., Merker, Jason D., Reuter, Chloe M., Sampson, Jacinda B., Smith, Kevin S., Waggott, Daryl M., Wheeler, Matthew T., Zastrow, Diane B., Zhao, Chunli, Allard, Patrick, Barseghyan, Hayk, Butte, Manish J., DellʼAngelica, Esteban C., Dipple, Katrina M., Dorrani, Naghmeh, Douine, Emilie D., Eskin, Ascia, Fogel, Brent L., Herzog, Matthew R., Lee, Hane, Loo, Sandra K., Martin, Martin G., Martínez-Agosto, Julian A., Nelson, Stan F., Palmer, Christina GS., Papp, Jeanette C., Parker, Neil H., Sinsheimer, Janet S., Vilain, Eric, Wan, Jijun, Yoon, Amanda J., Zheng, Allison, Behnam, Babak, Burke, Elizabeth A., DʼSouza, Precilla, Davids, Mariska, Draper, David D., Estwick, Tyra, Ferreira, Carlos, Godfrey, Rena A., Groden, Catherine A., Johnston, Jean M., Lau, C. Christopher, Macnamara, Ellen F., Maduro, Valerie V., Markello, Thomas C., Morimoto, Marie, Murphy, Jennifer L., Nehrebecky, Michele E., Novacic, Donna, Pusey, Barbara N., Sharma, Prashant, Toro, Camilo, Valivullah, Zaheer M., Wahl, Colleen E., Yu, Guoyun, Gropman, Andrea L., Adams, David R., Gahl, William A., Malicdan, May Christine V., Tifft, Cynthia J., Wolfe, Lynne A., Postlethwait, John H., Westerfield, Monte, Bican, Anna, Hamid, Rizwan, Newman, John H., Phillips, John A., III, Robertson, Amy K., and Cogan, Joy D.

Published
2018
Full Text
View/download PDF

26. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Author

Hamidi, Sarah, Iyer, Priyanka C., Dadu, Ramona, Gule-Monroe, Maria K., Maniakas, Anastasios, Zafereo, Mark E., Wang, Jennifer R., Busaidy, Naifa L., and Cabanillas, Maria E.

Subjects
ANAPLASTIC thyroid cancer, IMMUNOTHERAPY, THERAPEUTICS, PROGRESSION-free survival, OVERALL survival, SURGICAL excision
Abstract

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n = 23 in DT and n = 48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment (p = 0.427) and prior treatments with surgery (p = 0.864) and radiation (p = 0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p = 0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p = 0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Impact of Clinical Factors and Treatments on SMARCB1 (INI‐1)‐Deficient Sinonasal Carcinoma

Author

Contrera, Kevin J., primary, Shakibai, Nasim, additional, Su, Shirley Y., additional, Gule‐Monroe, Maria K., additional, Roberts, Dianna, additional, Brahimaj, Bledi, additional, Williams, Michelle D., additional, Ferrarotto, Renata, additional, Phan, Jack, additional, Gunn, Brandon, additional, Raza, Shaan, additional, DeMonte, Franco, additional, and Hanna, Ehab Y., additional

Published
2023
Full Text
View/download PDF

28. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series

Author

Contrera, Kevin J., primary, Gule-Monroe, Maria K., additional, Hu, Mimi I., additional, Cabanillas, Maria E., additional, Busaidy, Naifa L., additional, Dadu, Ramona, additional, Waguespack, Steven G., additional, Wang, Jennifer R., additional, Maniakas, Anastasios, additional, Lai, Stephen Y., additional, Diersing, Julia, additional, Kwon, Michael, additional, Grubbs, Elizabeth G., additional, Subbiah, Vivek, additional, Williams, Michelle D., additional, and Zafereo, Mark E., additional

Published
2023
Full Text
View/download PDF

29. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience

Author

Gregory, Timothy A, primary, Mastall, Maximilian, additional, Lin, Heather, additional, Hess, Kenneth R, additional, Yuan, Ying, additional, Martin-Bejarano Garcia, Manuela, additional, Fuller, Gregory N, additional, Alfaro, Kristin D, additional, Gule-Monroe, Maria K, additional, Huse, Jason T, additional, Khatua, Soumen, additional, Rao, Ganesh, additional, Sandberg, David I, additional, Wefel, Jeffrey S, additional, Yeboa, Debra N, additional, Paulino, Arnold C, additional, McGovern, Susan L, additional, Zaky, Wafik, additional, Mahajan, Anita, additional, Suki, Dima, additional, Weathers, Shiao-Pei, additional, Harrison, Rebecca A, additional, de Groot, John F, additional, Puduvalli, Vinay K, additional, Penas-Prado, Marta, additional, and Majd, Nazanin K, additional

Published
2023
Full Text
View/download PDF

31. PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer

Author

Vodopivec, Danica M, primary, Cabanillas, Maria E, additional, Busaidy, Naifa L, additional, Gule-Monroe, Maria K, additional, Zafereo, Mark E, additional, Wang, Jennifer R, additional, Williams, Michelle D, additional, Waguespack, Steven G, additional, Bassett, Roland, additional, Maniakas, Anastasios, additional, Lai, Stephen Y, additional, and Dadu, Ramona, additional

Published
2022
Full Text
View/download PDF

32. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

Author

Kabraji, Sheheryar, primary, Ni, Jing, additional, Sammons, Sarah, additional, Li, Tianyu, additional, Van Swearingen, Amanda E.D., additional, Wang, Yanzhi, additional, Pereslete, Alyssa, additional, Hsu, Liangge, additional, DiPiro, Pamela J., additional, Lascola, Chris, additional, Moore, Heather, additional, Hughes, Melissa, additional, Raghavendra, Akshara S., additional, Gule-Monroe, Maria, additional, Murthy, Rashmi K., additional, Winer, Eric P., additional, Anders, Carey K., additional, Zhao, Jean J., additional, and Lin, Nancy U., additional

Published
2022
Full Text
View/download PDF

33. Contrast Enhancement Patterns in Pediatric Glioblastomas

Author

Pokhylevych, Halyna, primary, Khose, Swapnil, additional, Gule-Monroe, Maria K., additional, Chen, Melissa M., additional, Fuller, Greg, additional, Gruschkus, Stephen K., additional, Sadighi, Zsila, additional, Zaky, Wafik, additional, Sandberg, David I., additional, McGovern, Susan L., additional, and Johnson, Jason M., additional

Published
2022
Full Text
View/download PDF

34. Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM)

Author

Kabraji, Sheheryar, primary, Ni, Jing, additional, Sammons, Sarah, additional, Van Swearingen, Amanda ED, additional, Wang, Yanzhi, additional, Pereslete, Alyssa M, additional, Hsu, Liangge, additional, Lascola, Chris, additional, Moore, Heather, additional, Hughes, Melissa, additional, Raghavendra, Akshara S, additional, Gule-Monroe, Maria, additional, Murthy, Rashmi K, additional, Winer, Eric P, additional, Anders, Carey K, additional, Zhao, Jean J, additional, and Lin, Nancy U, additional

Published
2022
Full Text
View/download PDF

37. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy

Author

Al Feghali, Karine A., primary, Fang, Penny, additional, Gule-Monroe, Maria, additional, Milgrom, Sarah, additional, Khoury, Joseph D., additional, Gunther, Jillian R., additional, Sheu, Tommy, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Shpall, Elizabeth J., additional, Nieto, Yago L., additional, Hosing, Chitra, additional, Nastoupil, Loretta J., additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Fowler, Nathan, additional, Flowers, Christopher, additional, Pinnix, Chelsea C., additional, and Dabaja, Bouthaina S., additional

Published
2021
Full Text
View/download PDF

38. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience

Author

Majd, Nazanin K, primary, Mastall, Maximilan, additional, Lin, Heather, additional, Dibaj, Seyede Shiva, additional, Hess, Kenneth R, additional, Yuan, Ying, additional, Garcia, Manuela Martin-Bejarano, additional, Fuller, Gregory N, additional, Alfaro, Kristin D, additional, Gule-Monroe, Maria K, additional, Huse, Jason T, additional, Khatua, Soumen, additional, Rao, Ganesh, additional, Sandberg, David I, additional, Wefel, Jeffrey S, additional, Yeboa, Debra N, additional, Paulino, Arnold C, additional, McGovern, Susan L, additional, Zaky, Wafik, additional, Mahajan, Anita, additional, Suki, Dima, additional, Weathers, Shiao-Pei, additional, Harriso, Rebecca A, additional, De Groo, John F, additional, Puduvalli, Vinay K, additional, and Penas-Prado, Marta, additional

Published
2021
Full Text
View/download PDF

40. Neoadjuvant selpercatinib for advanced medullary thyroid cancer

Author

Jozaghi, Yelda, primary, Zafereo, Mark, additional, Williams, Michelle D., additional, Gule‐Monroe, Maria K., additional, Wang, Jennifer, additional, Grubbs, Elizabeth G., additional, Vaporciyan, Ara, additional, Hu, Mimi I., additional, Busaidy, Naifa, additional, Dadu, Ramona, additional, Waguespack, Steven G., additional, Subbiah, Vivek, additional, and Cabanillas, Maria, additional

Published
2020
Full Text
View/download PDF

41. CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER

Author

Murthy, Rashmi, primary, O’Brien, Barbara, additional, Berry, Donald, additional, Navin, Nicholas, additional, Johnson, Jason, additional, Gule-Monroe, Maria, additional, Leone, Jose, additional, Specht, Jennifer, additional, Melisko, Michelle, additional, Morikawa, Aki, additional, Storniolo, Anna, additional, Brufsky, Adam, additional, Pohlmann, Paula, additional, Park, Deric, additional, Park, Ben, additional, Krop, Ian, additional, Lin, Nancy, additional, Rimawi, Mothaffar, additional, Wolff, Antonio, additional, Forero-Torres, Andres, additional, and Stringer-Reasor, Erica, additional

Published
2020
Full Text
View/download PDF

44. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).

Author

Cabanillas, Maria E., primary, Dadu, Ramona, additional, Ferrarotto, Renata, additional, Liu, Suyu, additional, Fellman, Bryan M., additional, Gross, Neil D., additional, Gule-Monroe, Maria, additional, Lu, Charles, additional, Grosu, Horiana, additional, Williams, Michelle D., additional, Duose, Dzifa Yawa, additional, Mallampati, Saradhi, additional, Dervin, Shannon, additional, Mckenna, Edward Francis, additional, Wang, Rui Jennifer, additional, Zafereo, Mark, additional, and Busaidy, Naifa Lamki, additional

Published
2020
Full Text
View/download PDF

46. Computer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors

Author

Zhou, Zijian, primary, Sanders, Jeremiah W., additional, Johnson, Jason M., additional, Gule-Monroe, Maria K., additional, Chen, Melissa M., additional, Briere, Tina M., additional, Wang, Yan, additional, Son, Jong Bum, additional, Pagel, Mark D., additional, Li, Jing, additional, and Ma, Jingfei, additional

Published
2020
Full Text
View/download PDF

47. Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer

Author

Murthy, Rashmi K, primary, O'Brien, Barbara J, additional, Hess, Ken R, additional, Navin, Nick, additional, Johnson, Jason, additional, Gule-Monroe, Maria, additional, Leone, Jose P, additional, Specht, Jennifer, additional, Melisko, Michelle, additional, Morikawa, Aki, additional, Storniolo, Anna M, additional, Brufsky, Adam, additional, Pohlmann, Paula R, additional, Park, Deric M, additional, Park, Ben H, additional, Krop, Ian, additional, Lin, Nancy U, additional, Wolff, Antonio, additional, Forerro-Torres, Andres, additional, and Stringer-Reasor, Erica, additional

Published
2020
Full Text
View/download PDF

48. RARE-47. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA; A RETROSPECTIVE REVIEW OF 200 PATIENTS AT MD ANDERSON CANCER CENTER

Author

Majd, Nazanin, primary, Mastall, Max, additional, Hess, Kenneth, additional, Fuller, Greg, additional, Alfaro-Munoz, Kristin, additional, Gule-Monroe, Maria, additional, Huse, Jason, additional, Khatua, Soumen, additional, Rao, Ganesh, additional, Sandberg, David I, additional, Wefel, Jeffrey, additional, Yeboa, Debra, additional, Zaky, Wafik, additional, Mahajan, Anita, additional, Puduvalli, Vinay, additional, Suki, Dima, additional, Weathers, Shiao-Pei, additional, Harrison, Rebecca, additional, DeGroot, John, additional, and Penas-Prado, Marta, additional

Published
2019
Full Text
View/download PDF

49. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib inBRAFV600E-Mutated Anaplastic Thyroid Carcinoma

Author

Wang, Jennifer R., primary, Zafereo, Mark E., additional, Dadu, Ramona, additional, Ferrarotto, Renata, additional, Busaidy, Naifa L., additional, Lu, Charles, additional, Ahmed, Salmaan, additional, Gule-Monroe, Maria K., additional, Williams, Michelle D., additional, Sturgis, Erich M., additional, Goepfert, Ryan P., additional, Gross, Neil D., additional, Lai, Stephen Y., additional, Gunn, Gary Brandon, additional, Phan, Jack, additional, Rosenthal, David I., additional, Fuller, Clifton David, additional, Morrison, William H., additional, Iyer, Priyanka, additional, and Cabanillas, Maria E., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results